Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666232 | 0.83 | HTT (0.72) | HTTP2RX1NR1H4EGLN1HDAC1 | |
| SCHEMBL13023090 | 0.81 | PTPN11 (0.55) | HTTNR1H4HDAC1MEN1KMT2A | |
| SCHEMBL23725396 | 0.81 | P2RX1 (0.55) | HTTP2RX1NR1H4ALDH1A1MAPT | |
| SCHEMBL10244256 | 0.81 | FADS1 (0.64) | P2RX1NR1H4GRM4MEN1KMT2A | |
| SCHEMBL13023051 | 0.80 | MEN1 (0.60) | HTTP2RX1NR1H4HDAC1MEN1 | |
| SCHEMBL13210705 | 0.79 | NAMPT (0.66) | HTTP2RX1NR1H4HDAC1GRM4 | |
| SCHEMBL28806576 | 0.79 | HTT (0.67) | HTTP2RX1NR1H4EGLN1HDAC1 | |
| SCHEMBL12700379 | 0.79 | HTT (1.00) | HTTP2RX1NR1H4EGLN1GRM4 | |
| Benzonitrile SCHEMBL29036464 | 0.78 | ALDH1A1 (0.49) | HTTALDH1A1MAPTIDO1 | |
| Hydrochloric Acid SCHEMBL2104599 | 0.78 | HTT (0.60) | HTTNR1H4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | HTT 196/4885P2RX1 3472/4885NR1H4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.